Characteristics of patients with high BRE expression (14 patients)
| . | Normal BRE-expressing patients . | High BRE-expressing patients* . | P . | ||
|---|---|---|---|---|---|
| Sex (N = 518), no. (%) | .788† | ||||
| Male | 252 | (50) | 6 | (42.9) | |
| Female | 252 | (50) | 8 | (57.1) | |
| Age (N = 518), y | .006‡ | ||||
| Median (range) | 47 | (14-77) | 37.5 | (17-49) | |
| WBC (N = 518), ×109/L | .500‡ | ||||
| Median (range) | 28.6 | (0.3-510) | 68 | (1-240) | |
| Transplantation status (N = 525), no. (%) | .130† | ||||
| No transplantation | 302 | (59.1) | 5 | (35.7) | |
| Autologous transplantation | 68 | (13.3) | 2 | (14.3) | |
| Allogeneic transplantation | 141 | (27.6) | 7 | (50) | |
| FAB classification (N = 509), no. (%) | < .001§ | ||||
| M0 | 17 | (3.4) | 1 | (7.1) | .400† |
| M1 | 100 | (20.2) | 0 | (0) | .083† |
| M2 | 130 | (26.3) | 1 | (7.1) | .130† |
| M3 | 23 | (4.6) | 0 | (0) | 1.000† |
| M4 | 93 | (18.8) | 0 | (0) | .084† |
| M5 | 104 | (21.0) | 12 | (85.7) | < .001† |
| M6 | 7 | (1.4) | 0 | (0) | 1.000† |
| Other/unknown | 21 | (4.2) | 0 | (0) | 1.000† |
| Cytogenetics, no. (%) | |||||
| t(15;17) (N = 522) | 25 | (4.9) | 0 | (0) | 1.000† |
| t(8;21) (N = 522) | 38 | (7.5) | 0 | (0) | .613† |
| inv(16) (N = 522) | 42 | (8.3) | 0 | (0) | .617† |
| 11q23 (N = 522) | 21 | (4.1) | 12 | (85.7) | < .001† |
| MLL-AF9 (N = 522) | 8 | (1.6) | 10 | (71.4) | < .001† |
| MLL-AF10 (N = 522) | 2 | (0.4) | 1 | (7.1) | .080† |
| MLL-ENL (N = 522) | 0 | (0) | 1 | (7.1) | .027† |
| Other genetic aberrations, no. (%) | |||||
| FLT3 ITD mutations (N = 525) | 143 | (28.0) | 0 | (0) | .015† |
| FLT3 TKD mutations (N = 523) | 51 | (10.0) | 2 | (14.3) | .643† |
| NPM1 mutations (N = 525) | 157 | (30.7) | 1 | (7.1) | .075† |
| CEBPA single mutations (N = 525) | 12 | (2.3) | 0 | (0) | 1.000† |
| CEBPA double mutations (N = 525) | 26 | (5.1) | 0 | (0) | 1.000† |
| EVI1 overexpression (N = 518) | 52 | (10.3) | 0 | (0) | .380† |
| IDH1 mutations (N = 522) | 38 | (7.5) | 0 | (0) | .613† |
| IDH2 mutations (N = 522) | 49 | (9.6) | 0 | (0) | .382† |
| . | Normal BRE-expressing patients . | High BRE-expressing patients* . | P . | ||
|---|---|---|---|---|---|
| Sex (N = 518), no. (%) | .788† | ||||
| Male | 252 | (50) | 6 | (42.9) | |
| Female | 252 | (50) | 8 | (57.1) | |
| Age (N = 518), y | .006‡ | ||||
| Median (range) | 47 | (14-77) | 37.5 | (17-49) | |
| WBC (N = 518), ×109/L | .500‡ | ||||
| Median (range) | 28.6 | (0.3-510) | 68 | (1-240) | |
| Transplantation status (N = 525), no. (%) | .130† | ||||
| No transplantation | 302 | (59.1) | 5 | (35.7) | |
| Autologous transplantation | 68 | (13.3) | 2 | (14.3) | |
| Allogeneic transplantation | 141 | (27.6) | 7 | (50) | |
| FAB classification (N = 509), no. (%) | < .001§ | ||||
| M0 | 17 | (3.4) | 1 | (7.1) | .400† |
| M1 | 100 | (20.2) | 0 | (0) | .083† |
| M2 | 130 | (26.3) | 1 | (7.1) | .130† |
| M3 | 23 | (4.6) | 0 | (0) | 1.000† |
| M4 | 93 | (18.8) | 0 | (0) | .084† |
| M5 | 104 | (21.0) | 12 | (85.7) | < .001† |
| M6 | 7 | (1.4) | 0 | (0) | 1.000† |
| Other/unknown | 21 | (4.2) | 0 | (0) | 1.000† |
| Cytogenetics, no. (%) | |||||
| t(15;17) (N = 522) | 25 | (4.9) | 0 | (0) | 1.000† |
| t(8;21) (N = 522) | 38 | (7.5) | 0 | (0) | .613† |
| inv(16) (N = 522) | 42 | (8.3) | 0 | (0) | .617† |
| 11q23 (N = 522) | 21 | (4.1) | 12 | (85.7) | < .001† |
| MLL-AF9 (N = 522) | 8 | (1.6) | 10 | (71.4) | < .001† |
| MLL-AF10 (N = 522) | 2 | (0.4) | 1 | (7.1) | .080† |
| MLL-ENL (N = 522) | 0 | (0) | 1 | (7.1) | .027† |
| Other genetic aberrations, no. (%) | |||||
| FLT3 ITD mutations (N = 525) | 143 | (28.0) | 0 | (0) | .015† |
| FLT3 TKD mutations (N = 523) | 51 | (10.0) | 2 | (14.3) | .643† |
| NPM1 mutations (N = 525) | 157 | (30.7) | 1 | (7.1) | .075† |
| CEBPA single mutations (N = 525) | 12 | (2.3) | 0 | (0) | 1.000† |
| CEBPA double mutations (N = 525) | 26 | (5.1) | 0 | (0) | 1.000† |
| EVI1 overexpression (N = 518) | 52 | (10.3) | 0 | (0) | .380† |
| IDH1 mutations (N = 522) | 38 | (7.5) | 0 | (0) | .613† |
| IDH2 mutations (N = 522) | 49 | (9.6) | 0 | (0) | .382† |